drugset / Trial / NCT01733186

Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects

NCT01733186 ↗

Phase 1/2 Completed 12 enrolled Medipost Co Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether CARTISTEM, a cell therapeutic product, is safe and effective in the treatment of articular cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.

Timeline

Start
2013-01-07
Primary completion
2017-06-02
Completion
2017-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject CARTISTEM Cell therapy 0.5 ml —

Indications